<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00332228</url>
  </required_header>
  <id_info>
    <org_study_id>5004-R</org_study_id>
    <secondary_id>R01DA010746</secondary_id>
    <nct_id>NCT00332228</nct_id>
  </id_info>
  <brief_title>Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence</brief_title>
  <official_title>Study Behavioral Naltrexone Therapy: A Novel Treatment for Heroin Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this research project is to test the efficacy of a newly developed&#xD;
      therapy, Behavioral Naltrexone Therapy (BNT), to enhance the success of naltrexone&#xD;
      maintenance and long-term abstinence for individuals with heroin dependence. This study&#xD;
      includes free detox and outpatient treatment for opioid dependence that includes medication&#xD;
      and a behavioral intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this Stage II project is to test the efficacy of a new combination of behavioral&#xD;
      therapy with oral naltrexone maintenance for the treatment of heroin addiction, and to test a&#xD;
      new long-acting depot parenteral formulation of naltrexone in initiating treatment.&#xD;
&#xD;
        1. Outpatient treatment with Behavioral Naltrexone Therapy will yield a lower rate of&#xD;
           relapse to illicit opiates compared to naltrexone plus compliance enhancement therapy.&#xD;
           Hypotheses:&#xD;
&#xD;
        2. Injections of depot naltrexone will reduce early attrition, improve initial&#xD;
           stabilization on oral naltrexone, and improve long-term outcome, particularly when&#xD;
           combined with Behavioral Naltrexone Therapy.&#xD;
&#xD;
        3. Patients who exhibit escalating levels of commitment language strength throughout one&#xD;
           early session of BNT will remain in treatment longer, will take more doses of&#xD;
           naltrexone, and will provide a higher percentage of opiate-free urines.&#xD;
&#xD;
        4. Increased commitment language strength on the part of the SO monitor will contribute&#xD;
           independently to the outcome of the identified patient, when controlling for patient&#xD;
           level commitment.&#xD;
&#xD;
      A critical objective of this current proposal is to improve retention, particularly in the&#xD;
      initial weeks of treatment. Preliminary work with a new depot formulation of naltrexone was&#xD;
      conducted (Comer et al, 1999, unpublished data), showing that it is well tolerated and&#xD;
      provides therapeutic blood levels and blockade of opiate effects for up to four weeks after a&#xD;
      single injection. By removing the option of stopping naltrexone to sample heroin, a common&#xD;
      mode of relapse, we hope to prevent early attrition and fully expose all patients to the&#xD;
      behavioral regimen of BNT, intended to shape strong compliance with oral naltrexone and&#xD;
      motivation for abstinence and lifestyle change.&#xD;
&#xD;
      160 heroin-dependent individuals seeking treatment will be recruited at PI (STARS) or&#xD;
      referred from other sites (e.g., private physician; other detoxification programs).&#xD;
      Prospective patients will be offered hospitalization for detoxification for rapid transition&#xD;
      to naltrexone followed by outpatient naltrexone maintenance and counseling for six months.&#xD;
      All enrolled participants will be encouraged to return for follow-up assessment visits at&#xD;
      one, three, and six months beyond the completion of their participation for research&#xD;
      purposes.&#xD;
&#xD;
      Patients will be randomly assigned to either the newly developed BNT or Compliance&#xD;
      Enhancement Therapy (CET), a manual-guided approach developed by Carroll and O'Malley at Yale&#xD;
      University as a control condition for psychotherapy studies with substance dependent&#xD;
      patients. Patients will also be randomly assigned to receive either active or placebo&#xD;
      injections of depot naltrexone prior to discharge from the detoxification. Therefore, there&#xD;
      will be four treatment conditions with 40 participants per condition. These four conditions&#xD;
      include: 1) BNT plus two doses of depot naltrexone prior to hospital discharge; 2) BNT plus&#xD;
      two placebo injections; 3) Compliance Enhancement (CE), simulating standard treatment with&#xD;
      oral naltrexone plus two depot naltrexone injections; and 4) CE plus two placebo injections.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2002</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proportion of patients relapsing to illicit opiates based on urine toxicology and self report.</measure>
    <time_frame>over 6 months of trial or length of participation</time_frame>
    <description>proportion of patients relapsing to opiate use</description>
  </primary_outcome>
  <primary_outcome>
    <measure>proportion of patients retained in treatment</measure>
    <time_frame>over course of 6 months of trial</time_frame>
    <description>proportion of patients retained over the course of the trial</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Opiate Dependence</condition>
  <arm_group>
    <arm_group_label>CE plus oral +depot naltrexone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Compliance enhancement (CE), simulating standard treatment with oral naltrexone plus two depot naltrexone;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CE plus oral naltrexone+ placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>CE with oral naltrexone plus two placebo injections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BNT plus Depot naltrexone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BNT plus two doses of depot naltrexone prior to hospital discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BNT plus PBO injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BNT plus two placebo injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>depot naltrexone</intervention_name>
    <description>long-acting depot parenteral formulation of naltrexone</description>
    <arm_group_label>BNT plus Depot naltrexone</arm_group_label>
    <arm_group_label>CE plus oral +depot naltrexone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Compliance enhancement (CE)</intervention_name>
    <description>Compliance enhancement (CE), simulating standard treatment with oral naltrexone</description>
    <arm_group_label>CE plus oral +depot naltrexone</arm_group_label>
    <arm_group_label>CE plus oral naltrexone+ placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BNT</intervention_name>
    <description>behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction</description>
    <arm_group_label>BNT plus Depot naltrexone</arm_group_label>
    <arm_group_label>BNT plus PBO injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult, aged 18-60. Clinical Interview.&#xD;
&#xD;
          2. Meets DSM-IV criteria for current opiate dependence disorder, supported by a positive&#xD;
             urine for opiates and a positive naloxone challenge test if the diagnosis is unclear.&#xD;
             If participating as an outpatient only, recent opiate dependence must be confirmed by&#xD;
             clinical history and/or communication with former treatment provider.&#xD;
&#xD;
             Clinical and SCID interview. Urine toxicology. Naloxone Challenge (see Procedures)&#xD;
             Communication with former treatment provider.&#xD;
&#xD;
          3. Able to give informed consent. Clinical interview and mental status exam&#xD;
&#xD;
          4. There must be one qualified significant other who is willing to be interviewed and&#xD;
             participate in program in order for a subject to be included in the study.&#xD;
&#xD;
        Clinical interview, and statement by significant other.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy, lactation, or failure in a sexually active woman to use adequate&#xD;
             contraceptive methods.&#xD;
&#xD;
             Clinical Interview, physical examination, serum pregnancy test&#xD;
&#xD;
          2. Active medical illness which might make participation hazardous, such as untreated&#xD;
             hypertension, acute hepatitis with SGOT or SGPT levels &gt;2-3 times normal, unstable&#xD;
             diabetes, chronic organic mental disorder (e.g., AIDS dementia).&#xD;
&#xD;
             Clinical Interview, physical examination, laboratory (Chem-20, CBC, urinalysis), ECG&#xD;
&#xD;
          3. Active psychiatric disorder which might interfere with participation or make&#xD;
             participation hazardous, including DSM-IV schizophrenia, bipolar disorder with mania&#xD;
             or psychosis, and depressive disorder with suicide risk or 1 or more suicide attempts&#xD;
             within the past year.&#xD;
&#xD;
             Clinical and SCID interview, clinical mental status examination, discussions with&#xD;
             previous psychiatrist or treatment provider if formerly in treatment.&#xD;
&#xD;
          4. History of allergic reaction to buprenorphine, naloxone, naltrexone, clonidine, or&#xD;
             clonazepam.&#xD;
&#xD;
             Clinical Interview&#xD;
&#xD;
          5. Currently prescribed or regularly taking opiates for chronic pain or medical illness.&#xD;
&#xD;
             Clinical Interview&#xD;
&#xD;
          6. Current participation in another intensive substance abuse treatment program.&#xD;
&#xD;
             Clinical Interview&#xD;
&#xD;
          7. Current participation in a methadone maintenance treatment program and/or regular use&#xD;
             of illicit methadone (&gt;30 mg per week). Clinical Interview; Urine toxicology.&#xD;
&#xD;
          8. Only available significant other is an active substance abuser, has an active&#xD;
             psychiatric or medical illness which would interfere with participation (e.g., chronic&#xD;
             psychosis, depression with suicide risk), or has a history of significant physical&#xD;
             violence with the participant.&#xD;
&#xD;
             Clinical Interview&#xD;
&#xD;
          9. History of accidental drug overdose in the last three years as defined as an episode&#xD;
             of opioid-induced unconsciousness or incapacitation, whether or not medical treatment&#xD;
             was sought or received.&#xD;
&#xD;
        Clinical Interview&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Nunes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STARS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stars.columbia.edu</url>
    <description>serive website</description>
  </link>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>May 30, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2006</study_first_posted>
  <last_update_submitted>October 25, 2012</last_update_submitted>
  <last_update_submitted_qc>October 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>opiate dependence</keyword>
  <keyword>heroin dependence</keyword>
  <keyword>naltrexone</keyword>
  <keyword>cognitive behavioral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

